Yoo Changhoon, Shin Sang Hyun, Park Joon-Oh, Kim Kyu-Pyo, Jeong Jae Ho, Ryoo Baek-Yeol, Lee Woohyung, Song Ki-Byung, Hwang Dae-Wook, Park Jin-Hong, Lee Jae Hoon
Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Korea.
Department of Surgery, Samsung Medical Center, School of Medicine, Sungkyunkwan University, Seoul 06351, Korea.
Cancers (Basel). 2021 Apr 1;13(7):1647. doi: 10.3390/cancers13071647.
Biliary tract cancers (BTCs) are a group of aggressive malignancies that arise from the bile duct and gallbladder. BTCs include intrahepatic cholangiocarcinoma (IH-CCA), extrahepatic cholangiocarcinoma (EH-CCA), and gallbladder cancer (GBCA). BTCs are highly heterogeneous cancers in terms of anatomical, clinical, and pathological characteristics. Until recently, the treatment of resectable BTC, including surgery, adjuvant chemotherapy, and radiation therapy, has largely been based on institutional practice guidelines and evidence from small retrospective studies. Recently, several large randomized prospective trials have been published, and there are ongoing randomized trials for resectable BTC. In this article, we review prior and recently updated evidence regarding surgery, adjuvant and neoadjuvant chemotherapy, and adjuvant radiation therapy for patients with resectable BTC.
胆道癌（BTCs）是一组起源于胆管和胆囊的侵袭性恶性肿瘤。BTCs包括肝内胆管癌（IH-CCA）、肝外胆管癌（EH-CCA）和胆囊癌（GBCA）。BTCs在解剖学、临床和病理学特征方面是高度异质性的癌症。直到最近，可切除BTC的治疗，包括手术、辅助化疗和放射治疗，很大程度上是基于机构实践指南和小型回顾性研究的证据。最近，几项大型随机前瞻性试验已经发表，并且正在进行针对可切除BTC的随机试验。在本文中，我们回顾了关于可切除BTC患者的手术、辅助和新辅助化疗以及辅助放射治疗的既往和最近更新的证据。
